Home >> Top News >> Roche launches IVD pan-TRK IHC assay

Roche launches IVD pan-TRK IHC assay

Print Friendly, PDF & Email

Nov. 29, 2018—Roche announced the worldwide launch of the Ventana pan-TRK (EPR17341) Assay, an automated in vitro diagnostic immunohistochemistry assay to detect tropomyosin receptor kinase proteins in cancer. The CE IVD/U.S. class I assay is designed to detect C-terminal protein expression, which allows for the detection of TRK-fusion as well as wild-type protein expression.

“As the first test of its kind, the Ventana pan-TRK (EPR17341) Assay provides an important new tool to help us better understand the role of TRK protein expression, particularly fusions in cancer,” Jill German, head of Roche tissue diagnostics, said in a press release. “We are excited to see the new information that results from the use of this important technology, and its ultimate impact for patients.”

The assay is available for use on the company’s BenchMark series of IHC/ISH automated staining instruments.


Check Also

Study: Kadcyla improved invasive disease-free survival

November 2018—Roche announced the phase three KATHERINE study met its primary endpoint, showing Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival) compared with trastuzumab as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment.